Axogen Inc. logo

Axogen Inc. (AXGN)

Market Open
8 Dec, 17:54
NASDAQ (CM) NASDAQ (CM)
$
31. 66
-1.66
-4.98%
$
1.31B Market Cap
- P/E Ratio
4% Div Yield
20,776 Volume
-0.19 Eps
$ 33.32
Previous Close
Day Range
31.52 33.14
Year Range
9.22 34.24
Want to track AXGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 78 days
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports 2024 Second Quarter Financial Results Call. At this time all participants are in a listen-only mode.

Seekingalpha | 1 year ago
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates

AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.

Zacks | 1 year ago
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?

AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?

AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks | 1 year ago
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Zacks | 1 year ago
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 1 year ago
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft

AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft

AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.

Zacks | 1 year ago